Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU's CHMP Gives Green Light To Three New Products And A New Indication For Afinitor

This article was originally published in The Pink Sheet Daily

Executive Summary

The EU's CHMP gave positive opinions on three new products – Novartis' glycopyrronium, AstraZeneca's ceftaroline and Takeda's teduglutide – and on a major new indication for Novartis’ everolimus (Afinitor), after its meeting on June 18-21.

Advertisement

Related Content

Acacia Pharma Raises $23.5 M Series B For Repurposing Drugs As Anti-Emetics
Despite Discount, High Price Again Fells Novartis’ Afinitor At NICE
Novartis Once-Daily COPD Combo Safe, Effective And Ready For Filing – Everywhere But In The U.S.
Gattex Goes To Advisory Panel With Positive Confirmatory Trial Data
Novartis To Increase Marketing Support As New Products Drive Growth In The Second Quarter
Novartis Finally Wins Arcapta Approval, Having Lost Battle On Desired Dose
Lots Of Activity In Forest Pipeline, But Can The Specialty Pharma Ever Put Lexapro Behind It?
AstraZeneca Sees Emerging Market Opportunity for Forest Anti-Infective
Swiss Pharma Nycomed Agrees To Market NPS’ Gattex Ex-U.S.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel